National Research Corporation (NASDAQ:NRC), the experience-improvement firm known as NRC Health, reported fourth-quarter results that signaled a steady operational turnaround, bolstered by a fifth consecutive quarter of growth in its core recurring contract base.
Pfizer (NYSE:PFE) announced positive topline results from the Phase 2b VESPER-3 study evaluating monthly maintenance dosing of its fully-biased, ultra-long-acting injectable GLP-1 receptor agonist PF’3944 (nexiguran ziclumeran) in adults with obesity or overweight without type 2 diabetes.
Pfizer (NYSE:PFE) reported fourth-quarter and full-year 2025 results on Tuesday, February 3, 2026, signaling a definitive shift away from its pandemic-era reliance.
Merck (NYSE:MRK) today reported fourth-quarter and full-year 2025 results that showcased a tale of two portfolios: a surging oncology and respiratory business set against a dramatic collapse in vaccine demand from China.
Vertex Pharmaceuticals (NASDAQ:VRTX) and WuXi Biologics announced a major license and research service agreement on Monday, February 2, 2026, aimed at developing an innovative trispecific T-cell Engager (TCE) for B-cell mediated autoimmune diseases.
Leiden, Netherlands-based Pharming Group (NASDAQ:PHARM) provided 2026 financial guidance and detailed its rare disease pipeline at its Investor Day on February 3, 2026.
The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan), a TROP2-directed antibody-drug conjugate (ADC).
Twist Bioscience (NASDAQ:TWST) reported first-quarter fiscal 2026 results Monday that beat revenue expectations and showed significant margin improvement, as the company stays on track to reach its profitability goals by the end of the year.
Sagimet Biosciences (NASDAQ:SGMT) announced Monday that its China-based partner, Ascletis Pharma, reported positive topline results from a Phase 3 open-label safety study of denifanstat (ASC40) in patients with moderate to severe acne.
Harrow (NASDAQ:HROW) reaffirmed its full-year 2025 revenue guidance of $270 million to $280 million on Monday, signaling confidence in its growing branded portfolio despite a strategic exit from the California compounding market.
ImmunityBio (NASDAQ:IBRX) announced Monday the launch of ResQ215B, a Phase 2 clinical study evaluating a novel, outpatient immunotherapy combination for patients with indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström’s Macroglobulinemia.
TuHURA Biosciences (NASDAQ:HURA) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead immune-priming candidate, IFx-2.0, for the treatment of stage IIB to stage IV cutaneous melanoma.
